Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30073859 | 1.00 | NPSR1 (0.33) | NPSR1HDAC6AAK1MMP13HDAC1 | |
| SCHEMBL24490826 | 1.00 | NPSR1 (0.33) | NPSR1HDAC6AAK1MMP13HDAC1 | |
| SCHEMBL5559416 | 0.82 | CTSK (0.34) | HDAC6AAK1MMP13HDAC1HDAC2 | |
| SCHEMBL4299159 | 0.82 | CTSK (0.34) | HDAC6AAK1MMP13HDAC1HDAC2 | |
| SCHEMBL8274243 | 0.82 | CTSK (0.34) | HDAC6AAK1MMP13HDAC1HDAC2 | |
| SCHEMBL25165406 | 0.82 | HDAC6 (0.33) | NPSR1HDAC6HDAC1HDAC2 | |
| SCHEMBL9177642 | 0.81 | HDAC6 (0.33) | NPSR1HDAC6HDAC1HDAC2 | |
| SCHEMBL9173643 | 0.81 | HDAC6 (0.33) | NPSR1HDAC6HDAC1HDAC2 | |
| SCHEMBL23193949 | 0.79 | NPSR1 (0.33) | NPSR1HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL29292095 | 0.79 | AAK1 (0.32) | NPSR1AAK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | MCL1, BCL9, BCL9L | NPSR1 3578/4885HDAC6 259/4885AAK1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.